The GoodRx Prescription Savings Blog

The latest updates on prescription drugs and ways to save from the GoodRx medical team

New Micardis Generic Approved: Telmisartan

by The GoodRx Pharmacist on January 13, 2014 at 1:29 pm

Telmisartan, the generic version of Micardis, was approved last week by the FDA for the treatment of hypertension (high blood pressure) and reducing the risk of cardiovascular events like heart attack or stroke.

What is telmisartan (Micardis), and what similar drugs are available?
Telmisartan is an angiotension receptor blocker (aka ARB). This class of medications is often reserved for those patients who are unable to tolerate a different type of blood pressure reducing medications known as ACE inhibitors. Other medications available in this class include Diovan (valsartan), Edarbi, (azilsartan), and Benicar (olmesartan). Avapro (irbesartan), Cozaar (losartan), Atacand (candesartan), and Teveten (eprosartan) are also available as generics.

How does it work?

These medications work by blocking the actions of chemicals in the body that cause blood vessel narrowing, which in turn leads to high blood pressure.

How is telmisartan usually taken?
Telmisartan and Micardis are available as 20 mg, 40 mg, and 80 mg tablets, and are usually taken ONCE DAILY with or without food.

What are the common side effects?

These medications can cause dizziness, lightheadedness, stuffy or runny nose, and stomach issues.

Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.